Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial

Bomback, A. S., Kavanagh, D., Vivarelli, M., Meier, M., Wang, Y., Webb, N. J. A., Trapani, A. J., & Smith, R. J. H. (2022). Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial. Kidney International Reports, 7(10), 2150–2159. https://doi.org/10.1016/j.ekir.2022.07.004
Authors:
Andrew S. Bomback
David Kavanagh
Marina Vivarelli
Matthias Meier
Yaqin Wang
Nicholas J.A. Webb
Angelo J. Trapani
Richard J.H. Smith
Affiliated Authors:
Andrew S. Bomback
Author Keywords:
alternative pathway
c3g
clinical trials
complement system
factor b
iptacopan
lnp023
Publication Type:
Article
Unique ID:
10.1016/j.ekir.2022.07.004
Publication Date:
Data Source:
Scopus

Record Created: